190 related articles for article (PubMed ID: 28853334)
21. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
Pinelli A; Godio C; Laghezza A; Mitro N; Fracchiolla G; Tortorella V; Lavecchia A; Novellino E; Fruchart JC; Staels B; Crestani M; Loiodice F
J Med Chem; 2005 Aug; 48(17):5509-19. PubMed ID: 16107150
[TBL] [Abstract][Full Text] [Related]
22. Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma.
Khanna S; Sobhia ME; Bharatam PV
J Med Chem; 2005 Apr; 48(8):3015-25. PubMed ID: 15828840
[TBL] [Abstract][Full Text] [Related]
23. Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.
Sohn YS; Park C; Lee Y; Kim S; Thangapandian S; Kim Y; Kim HH; Suh JK; Lee KW
J Mol Graph Model; 2013 Nov; 46():1-9. PubMed ID: 24104184
[TBL] [Abstract][Full Text] [Related]
24. Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode.
Capelli D; Cerchia C; Montanari R; Loiodice F; Tortorella P; Laghezza A; Cervoni L; Pochetti G; Lavecchia A
Sci Rep; 2016 Oct; 6():34792. PubMed ID: 27708429
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists.
Fracchiolla G; Laghezza A; Piemontese L; Parente M; Lavecchia A; Pochetti G; Montanari R; Di Giovanni C; Carbonara G; Tortorella P; Novellino E; Loiodice F
Bioorg Med Chem; 2012 Mar; 20(6):2141-51. PubMed ID: 22341573
[TBL] [Abstract][Full Text] [Related]
26. Interaction models of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids against PPARalpha and PPARgamma: molecular modeling and comparative molecular similarity indices analysis studies.
Cheng F; Shen J; Xu X; Luo X; Chen K; Shen X; Jiang H
Protein Pept Lett; 2009; 16(2):150-62. PubMed ID: 19200038
[TBL] [Abstract][Full Text] [Related]
27. Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
Kim SO; Han Y; Ahn S; An S; Shin JC; Choi H; Kim HJ; Park NH; Kim YJ; Jin SH; Rho HS; Noh M
Bioorg Med Chem; 2018 Nov; 26(21):5654-5663. PubMed ID: 30352713
[TBL] [Abstract][Full Text] [Related]
28. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
[TBL] [Abstract][Full Text] [Related]
29. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
Fracchiolla G; Laghezza A; Piemontese L; Tortorella P; Mazza F; Montanari R; Pochetti G; Lavecchia A; Novellino E; Pierno S; Conte Camerino D; Loiodice F
J Med Chem; 2009 Oct; 52(20):6382-93. PubMed ID: 19775169
[TBL] [Abstract][Full Text] [Related]
30. A Molecular Dynamics-Shared Pharmacophore Approach to Boost Early-Enrichment Virtual Screening: A Case Study on Peroxisome Proliferator-Activated Receptor α.
Perricone U; Wieder M; Seidel T; Langer T; Padova A; Almerico AM; Tutone M
ChemMedChem; 2017 Aug; 12(16):1399-1407. PubMed ID: 28135036
[TBL] [Abstract][Full Text] [Related]
31. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.
Piemontese L; Fracchiolla G; Carrieri A; Parente M; Laghezza A; Carbonara G; Sblano S; Tauro M; Gilardi F; Tortorella P; Lavecchia A; Crestani M; Desvergne B; Loiodice F
Eur J Med Chem; 2015 Jan; 90():583-94. PubMed ID: 25497132
[TBL] [Abstract][Full Text] [Related]
34. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.
Chen KC; Chang SS; Huang HJ; Lin TL; Wu YJ; Chen CY
J Biomol Struct Dyn; 2012; 30(6):662-83. PubMed ID: 22731403
[TBL] [Abstract][Full Text] [Related]
35. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
36. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Fiévet C; Fruchart JC; Staels B
Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
[TBL] [Abstract][Full Text] [Related]
37. A computational study to identify the key residues of peroxisome proliferator-activated receptor gamma in the interactions with its antagonists.
Sharifi T; Ghayeb Y
J Biomol Struct Dyn; 2018 May; 36(7):1822-1833. PubMed ID: 28566016
[TBL] [Abstract][Full Text] [Related]
38. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
[TBL] [Abstract][Full Text] [Related]
39. New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.
Laghezza A; Pochetti G; Lavecchia A; Fracchiolla G; Faliti S; Piemontese L; Di Giovanni C; Iacobazzi V; Infantino V; Montanari R; Capelli D; Tortorella P; Loiodice F
J Med Chem; 2013 Jan; 56(1):60-72. PubMed ID: 23171045
[TBL] [Abstract][Full Text] [Related]
40. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
